Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors
This study is an an open-label Phase I trial of VT1021 in patients with advanced solid tumors. Patients must have recurrent or advanced cancer (i.e., solid tumors) for which standard therapy offers no curative potential.
A Phase 1 Study Evaluating the Safety, Pharmacology, and Preliminary Activity of VT1021 in Patients with Advanced Solid Tumors
- ClinicalTrials.gov Identifier: NCT03364400
- Protocol Number: 18-609
- Principal Investigator: Andrea Bullock
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required